Agreements, Orphan Drug Designations, and Management Changes - Analyst Notes on Medtronic, DARA BioSciences, Sequenom, AcelRx and Pernix

NEW YORK, June 19, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Medtronic, Inc. (NYSE: MDT), DARA BioSciences, Inc (NASDAQ: DARA), Sequenom Inc. (NASDAQ: SQNM), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) and Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3874-100free.

--
Medtronic, Inc. Analyst Notes
On June 15, 2014, Medtronic, Inc. (Medtronic) announced that the Company, along with Covidien plc, has entered into a definitive agreement under which the Company will acquire Covidien in a cash-and-stock transaction valued at $93.22 per Covidien share, or a total of approximately $42.9 billion, based on Medtronic's closing stock price of $60.70 per share as of June 13, 2014. Additionally, the Board of Directors of both companies have unanimously approved of the transaction. Commenting on the acquisition, Medtronic Chairman and CEO, Omar Ishrak, stated, "We are excited to reach this agreement with Covidien, which further advances our mission to alleviate pain, restore health and extend life for patients around the world. This acquisition will allow Medtronic to reach more patients, in more ways and in more places." The Company stated that the transaction is expected to close in Q4 2014 or early 2015. The full analyst notes on Medtronic are available to download free of charge at:

http://www.analystsreview.com/Jun-19-2014/MDT/report.pdf

--
DARA BioSciences, Inc Analyst Notes
On June 16, 2014, DARA BioSciences, Inc. (DARA BioSciences) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the experimental compound KRN5500 for the treatment of multiple myeloma. According to the Company, KRN5500, a novel, intravenous, non-opioid, non-narcotic compound, is currently in Phase 2 clinical development. Additionally, the Company stated that Orphan Drug Designation provides it seven years market exclusivity from the time of approval, tax credits, and the waiver of PDUFA filing fees, as well as access to federal grants. DARA BioSciences CEO and Chief Medical Officer, David J. Drutz, M.D., stated, "This second orphan drug designation for our key development asset KRN5500 allows us to approach the actual treatment of multiple myeloma, whereas the CCIPN designation is specific to neuropathy. We believe this myeloma-specific orphan designation enhances both the viability and the future market opportunity for this valuable pipeline product." The full analyst notes on DARA BioSciences are available to download free of charge at:

http://www.analystsreview.com/Jun-19-2014/DARA/report.pdf

--
Sequenom Inc. Analyst Notes
On June 9, 2014, Sequenom Inc. (Sequenom) announced that Sequenom Laboratories, the Company's wholly-owned subsidiary, has signed a national agreement with a leading health insurance company covering 13 million people throughout the U.S. for providing MaterniT21™ PLUS laboratory-developed test (LDT) to the additional 13 million people, bringing the total number of covered lives under agreement by Sequenom Laboratories' diagnostic services to more than 140 million. Sequenom President and Chief Operating Officer, William Welch, stated, "This new payor agreement is a testament to the continued acceptance and adoption of noninvasive prenatal testing (NIPT), and we are proud to maintain our position as a market leader in this innovative and rapidly growing area." The full analyst notes on Sequenom are available to download free of charge at:

http://www.analystsreview.com/Jun-19-2014/SQNM/report.pdf

--
AcelRx Pharmaceuticals, Inc. Analyst Notes
On June 2, 2014, AcelRx Pharmaceuticals, Inc. (AcelRx) announced that Company Chief Commercial Officer, David Chung, has resigned in order to assume the role of CEO for a medical device company. The Company stated that until a suitable replacement is found, AcelRx President and CEO, Richard King, will assume the duties and responsibilities of Chief Commercial Officer along with leading the continued build-out of the commercial organization and launch preparation for Zalviso. Commenting on the resignation, King said, "David has laid a solid foundation and began the build of a commercial team that will continue the pre-commercial activities for Zalviso. We anticipate no delay in our commercial launch plans pending a positive PDUFA. We also wish David success in his new endeavor." The full analyst notes on AcelRx are available to download free of charge at:

http://www.analystsreview.com/Jun-19-2014/ACRX/report.pdf

--
Pernix Therapeutics Holdings, Inc. Analyst Notes
On June 16, 2014, Pernix Therapeutics Holdings, Inc.'s (Pernix) stock increased by 11.29%, ending the day at $8.08. Over the past five-day trading session, Pernix's stock went up by 14.94%, compared to the Nasdaq Composite which dipped by 0.35% during the same trading period. The full analyst notes on Pernix are available to download free of charge at:

http://www.analystsreview.com/Jun-19-2014/PTX/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com .

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com .

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review